Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Part 1 and 2:~* Chinese participant who must be at least 20 years of age~* Documented multiple myeloma (MM) with measurable disease according to protocol-defined criteria~* Relapsed or refractory multiple myeloma after receiving at least 2 prior lines of therapy~* Eastern Cooperative Oncology Group performance status score of 0, 1, or 2~* Adequate recovery from prior therapy~Part 3:~* Chinese participants who must be at least 18 years of age~* Received both a proteasome inhibitor (PI) (greater than or equal to \[\>=\] 2 cycles or 2 months of treatment) and an immunomodulatory drug (IMiD) (\>=2 cycles or 2 months of treatment) in any order during the course of treatment (except for participants who discontinued either of these treatments due to a severe allergic reaction within the first 2 cycles/months)~* Documented evidence of progressive disease (PD) based on investigator's determination of response as defined by the International Myeloma Working Group (IMWG) criteria on or after their last regimen~Exclusion Criteria:~Part 1 and 2:~* Received daratumumab or other anti-CD38 therapies previously~* Previously received an allogenic stem cell transplant or has received an autologous stem cell transplantation within 12 weeks~* Exhibiting clinical signs of meningeal involvement of multiple myeloma~* Known chronic obstructive pulmonary disease, known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification~* Known clinically significant cardiac disease~* Known to be seropositive for human immunodeficiency virus, hepatitis B or known to have a history of hepatitis C~* Has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis~* Abnormal laboratory values according to protocol-defined parameters at screening~Part 3:~- Received anti-myeloma treatment within 2 weeks before Cycle 1, Day 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Dose Escalation Part (Type: EXPERIMENTAL): Participants will receive single dose of daratumumab from Week 1 till Week 3 (Period 1 - single dosing period) followed by 6 weekly doses of daratumumab until Week 9 (Period 2 - weekly dosing period) and every 2 weeks for 8 infusions and then once every 4 weeks from Week 26 until disease progression, intolerability, or other reasons for treatment discontinuation (Period 3 - less intense dosing period). A dose of 8 milligram per kilogram (mg/kg) will be chosen as the starting dose and will be escalated to 16 mg/kg if the 8 mg/kg is determined safe and tolerated by study evaluation team (SET).
- Part 2: Pharmacokinetic (PK) Expansion Part (Type: EXPERIMENTAL): Participants will receive daratumumab at 16 mg/kg in 3 periods as given in the Part 1.
- Part 3: Safety Expansion Part (Type: EXPERIMENTAL): Participants will receive daratumumab 16 mg/kg every week for 8 weeks followed by every 2 weeks for an additional 16 weeks, and then every 4 weeks thereafter. Participants will be treated with daratumumab until disease progression, intolerability, or any other reasons for treatment discontinuation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete